Research - Role of primary care in PBC management: clinician perspectives needed
Thursday, 09 March 2017 11:36
The University of Birmingham and NIHR Birmingham Liver BRU in conjunction with UK-PBC are conducting research into perspectives of patients, GPs and specialists around PBC care and potential future changes including an increased role for primary care. We are looking for gastroenterologists and hepatologists in the West Midlands area to take part in qualitative interviews around the role of stratification. Please see advert below for further details or contact the study team led by Gideon Hirschfield for more details.
- Download advert [ 40 kb ]
IBD Registry: March Headlines
Wednesday, 01 March 2017 10:25
IBD Registry 2017 Roadshow Dates Announced
- MON 15th MAY EXETER
- THURS 18th MAY CARDIFF
- FRI 19th MAY SHEFFIELD
- TUES 23rd MAY DARLINGTON
- FRI 2nd JUNE LONDON
- FRI 9th JUNE BIRMINGHAM
- AUTUMN 2017 GLASGOW
A series of half-day meetings to support clinical teams as they join the IBD Registry. The sessions provide protected time for teams to learn about the Biologics Audit and QI programme using the IBD Registry, and to develop local plans for Registry adoption. Each meeting will be tailored to local needs and aim to provide information, support and hands-on guidance. Experts from the Registry will be on hand to answer questions, and interactive workshops will provide practical support for teams to work together to develop your own plans. Free to attend due to generous industry sponsorship. Register at http://ibdrroadshow2017.eventreference.com/
Trusts in England – 40% discount on audit subscriptions by 15th March
We've had an encouraging response to the request for subscriptions from Trusts in England to help the BSG maintain the Biologics Audit now that NHS England funding has been withdrawn.
At £2,500 per annum, the subscription is significantly less than the cost of one patient on biologics treatment for a year. Subscribers will receive benchmarked quarterly reports on the Biologics Audit KPIs focusing on quality improvement topics recommended in the last RCP Biologics Report. Later in the year, it is our intention to include reporting of HES data in relation to the Biologics data.
The BSG has offered to reduce the cost in the first year by 40% if a Trust provides a purchase order by 15th March 2017. We have written to the Chief Executives of all Trusts in England explaining the new arrangements for the Biologics Audit, putting the subscription cost in the context of overall expenditure on biologics for IBD, and reminding them that participation in the Audit is part of the NHS England Quality Accounts requirement.
DID YOU KNOW?
- Teams can participate in the IBD Registry using their own choice of data entry systems to suit local needs (including some existing local systems)
- Being part of the IBD Registry will give teams:
- Robust local data to manage their biologics patients and IBD service more effectively, efficiently and safely
- Evidence to benchmark the quality of their service as part of a national audit of the safety and appropriate use of biologics
With our thanks for your continued contribution to the IBD Registry,
Dr Stuart Bloom, IBD Registry Chair & Dr Fraser Cummings, IBD Registry Clinical Lead
DATES FOR YOUR DIARY:
- MON 15th MAY EXETER ROADSHOW
- THURS 18th MAY CARDIFF ROADSHOW
- FRI 19th MAY SHEFFIELD ROADSHOW
- TUES 23rd or WED 24th MAY DARLINGTON ROADSHOW
- FRI 2nd JUNE LONDON ROADSHOW
- FRI 9th JUNE BIRMINGHAM ROADSHOW
- WED 21 JUNE: IBD REGISTRY SYMPOSIUM AT BSG ANNUAL MEETING, MANCHESTER
- AUTUMN: GLASGOW ROADSHOW
- DECEMBER : Publication of the IBD Registry initial report
UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
Thursday, 23 February 2017 11:47
Alenka J Brooks, Philip J Smith, Richard Cohen, Paul Collins, Andrew Douds, Valda Forbes, Daniel R Gaya, Brian T Johnston, Patrick J McKiernan Charles D Murray, Shaji Sebastian, Monica Smith, Lisa Whitley, Lesley Williams, Richard K Russell, Sara A McCartney, James O Lindsay
The risks of poor transition include delayed and inappropriate transfer that can result in disengagement with healthcare. Structured transition care can improve control of chronic digestive diseases and long-term health-related outcomes. These are the first nationally developed guidelines on the transition of adolescent and young persons (AYP) with chronic digestive diseases from paediatric to adult care. They were commissioned by the Clinical Services and Standards Committee of the British Society of Gastroenterology under the auspices of the Adolescent and Young Persons (A&YP) Section. Electronic searches for English-language articles were performed with keywords relating to digestive system diseases and transition to adult care in the Medline (via Ovid), PsycInfo (via Ovid), Web of Science and CINAHL databases for studies published from 1980 to September 2014. The quality of evidence and grading of recommendations was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The limited number of studies in gastroenterology and hepatology required the addition of relevant studies from other chronic diseases to be included.
These guidelines deal specifically with the transition of AYP living with a diagnosis of chronic digestive disease and/or liver disease from paediatric to adult healthcare under the following headings;
- Patient populations involved in AYP transition
- Risks of failing transition or poor transition
- Models of AYP transition
- Patient and carer/parent perspective in AYP transition
- Surgical perspective
- UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care [ 0.9 Mb ]
NICE guidance on molecular testing strategies for Lynch syndrome in people with colorectal cancer
Monday, 27 February 2017 14:02
An estimated 175,000 people have Lynch syndrome in the UK, however 95% of those do not know they have it. NICE recommends that microsatellite instability (MSI) testing or immunohistochemistry (IHC) should be used on all colorectal cancers, when first diagnosed, to detect abnormalities that might mean the presence of Lynch Syndrome. Where these tests show the person has a risk of having Lynch syndrome, the guidance recommends that further tests are carried out to confirm the diagnosis. Because Lynch Syndrome is an inherited condition, a positive test can also lead to testing for family members. While these tests have been available for a while, there is currently wide variation in the provision of testing for Lynch syndrome and other inherited colorectal cancers. Expanding testing to all people with colorectal cancer will increase the detection of Lynch syndrome and identify families who could benefit from genetic testing to determine if other family members have the condition. This could lead to increased surveillance and consequently improved patient outcomes through earlier diagnosis and treatment.
Page 1 of 13